X
X
Top

Cipla all set to launch anti-viral drug Favipiravir for treatment of coronavirus patients

Cipla all set to launch anti-viral drug Favipiravir for treatment of coronavirus patients
x

Favipiravir Anti-Viral Drug

Highlights

Pharmaceutical Company Cipla is all set to launch the anti-viral drug Favipiravir for the treatment of COVID-19 patients.

Pharmaceutical Company Cipla is all set to launch the anti-viral drug Favipiravir for the treatment of COVID-19 patients. A top government research institute, Council of Scientific and Industrial Research (CSIR) has played an important role in the process by transferring the cost-effective technology to Cipla.

Director CSIR-IICR, Dr S Chandrashekhar said, the technology provided by the Institute is very efficient and affordable. He said, it allows the company to make large quantities of drugs within a short span of time.

An off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for the treatment of COVID-19 patients, especially in mild and moderate cases.

Director General of CSIR, Dr Shekhar Mande said, CSIR is working with the industry in developing products for mitigation of Covid-19. He said, partnership with Cipla is an example that CSIR is committed to bringing repurposed drugs on a fast track.

CSIR-Indian Institute of Chemical Technology (CSIR-IICT) developed a cost-effective process using locally available chemicals to synthesise this Active Pharmaceutical Ingredient (API) and transferred the technology to the Cipla Company.

Anti-viral drug Favipiravir has shown promising results in clinical trials for the treatment of Covid-19 patients especially in the mild and moderate patients.

Drug Controller General of India has given restricted emergency use for Favipiravir in the country.

Show Full Article
Print Article
Download The Hans India Android App or iOS App for the Latest update on your phone.
Subscribed Failed...
Subscribed Successfully...
Next Story
More Stories